AstraZeneca And Daiichi’s Dato-DXd Set For More Modest Market Entry Than First Hoped

 
• By Andrew McConaghie
  
Daria Artemenko/Alamy Stock Photo
(Daria Artemenko / Alamy Stock Ph/Alamy Stock Photo)

More from Anticancer

More from R&D